Source : https://www.spireresearch.com/newsroom/spirethoughts/130808_indias-generic-drug-industry-heading-for-change/

India’s generic drug industry heading for change


The India Supreme Court recently rejected drug maker Novartis AG’s attempt to patent an updated version of a cancer drug. This would ensure patients across the globe would have access to cheaper versions of lifesaving medicines, such as Glivec, that is used to treat chronic myeloid leukemia. With a generic and more affordable medicine available at a huge price difference, this could be the difference between life and death.

On the other hand, this decision also means that India’s USD26 billion generic drug industry, which supplies most cheap medicines across the developing world could slow down. Many other international pharmaceutical companies are now re-thinking their strategies for the Indian market. Nonetheless, it signifies that Indian companies will now have added legal coverage to produce and export low-cost generic drugs.

How would giving the world access to cheaper medicines affect India?


About Spire Research and Consulting

Spire Research and Consulting is the leading research consultancy in global emerging markets. Spire's competitive advantage lies in its ability to deliver actionable intelligence on the external business environment in support of its clients’ strategic decision-making in marketing and business development. Spire's clients include 50 Global Fortune 1000 companies and government agencies in 15 countries. For more information, please visit www.spireresearch.com.


For media enquiries, please contact:

Alyssa Tan
Manager, Group Corporate Communications
Spire Research and Consulting
Phone: (65) 6838 5355
E-mail: alyssa.tan@spireresearch.com

Nidhi Singh
Executive, Corporate Communications
Spire Research and Consulting
Phone: (91) 124 654 2062
E-mail: nidhi.singh@spireresearch.com